Key result
The novel R1905X DYSF founder mutation in homozygosity produced 3 different dysferlinopathy phenotypes without intrafamilial heterogeneity in all 8 evaluated patients from Spain.
Observational (n=8)
The identification of the R1905X DYSF founder mutation in a Spanish population highlights phenotypic variability in dysferlinopathies and provides a homogeneous cohort for studying modifying factors.
Answers are grounded in this paper and cite their sources.
Variable phenotypes in this founder cohort warrant cautious prognosis counseling; leaves open modifier identification in homogeneous dysferlinopathy patients.
BACKGROUND: Mutations in the dysferlin (DYSF) gene cause 3 different phenotypes of muscular dystrophies: Miyoshi myopathy, limb-girdle muscular dystrophy type 2B, and distal anterior compartment myopathy. OBJECTIVE: To present the results of clinical and molecular analysis of 8 patients with dysferlinopathy from 5 unrelated families. DESIGN: Clinical assessment was performed with a standardized protocol. A muscle biopsy specimen was obtained and studied by immunohistochemistry. Genetic analysis was performed using single-stranded conformation polymorphism and direct sequencing of genomic DNA. RESULTS: All the patients presented the R1905X mutation in the DYSF gene in homozygosity, and the haplotype analysis at the DYSF locus revealed that it was a novel and founder mutation. A C-to-T transition at nucleotide position 6086 changes an arginine into a stop codon, leading to premature termination of translation. This mutation was expressed as 3 different clinical phenotypes (limb-girdle muscular dystrophy type 2B, Miyoshi distal myopathy, and distal anterior dysferlinopathy), but only 1 phenotype was found in the same family. CONCLUSIONS: The new R1905X DYSF founder mutation produced the 3 possible dysferlinopathy phenotypes without intrafamilial heterogeneity. This homogeneous population in Sueca, Spain, should be helpful in studying the modifying factors responsible for the phenotypic variability.
No takes yet. Share an insight, caveat, or question.
Vílchez et al. (2005) conducted an observational in dysferlinopathy (n=8). R1905X mutation in the DYSF gene was evaluated on Clinical phenotypes. The novel R1905X DYSF founder mutation in homozygosity produced 3 different dysferlinopathy phenotypes without intrafamilial heterogeneity in all 8 evaluated patients from Spain.
Synapse has enriched 10 related papers. Consider them for comparative context: